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Section 1: Abstract 
Relationship Between Preoperative Statin Use And Postoperative Infectious 
Complications in General and Non-Cardiac Surgery 
Johnathan A. Bernard1,2, Ronnie A. Rosenthal1, Selwyn O. Rogers2  
1: Department of Surgery, West Haven VA Medical Center, Yale University School of 
Medicine, New Haven, CT 
2: Center for Surgery and Public Health, Harvard School of Public Health, Boston, MA 
 
Objective: 
Characterize the impact of preoperative statin use on postoperative infectious 
complications and 30-day postoperative mortality in general and non-cardiac surgery 
patients.  
Background: 
The lipid lowering effects of statins have been well documented for the treatment of 
coronary artery disease. There has been mounting evidence to support use of statins for 
their pleiotropic effect. Among these, immune system modulation, improved endothelial 
function, attenuation of sepsis, and organ protection are particularly relevant to the 
surgical patient. However, the pleiotropic effects of statins are poorly understood 
postoperatively in general and non-cardiac surgery patients. 
Design: 
Retrospective observational study conducted to test the hypothesis that preoperative statin 
use leads to a risk reduction of postoperative infectious complications (POIC) (any 
occurrence of surgical site infection, deep surgical site infection, wound dehiscence, 
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pneumonia, urinary tract infection, sepsis, or septic shock) and would reduce the risk of 
30 day postoperative mortality, while identifying independent risk factors for POIC. To 
do so, the ACS NSQIP database at a 777-bed academic medical center was merged with 
pharmacy data and electronic medical records at the same institution from January 1, 
2006 to January 1, 2008.  
Results: 
Two thousand, five hundred and eighty four patients underwent major general and non-
cardiac surgery during the study time period. Five hundred and seventy eight of these 
patients were on statin therapy before admission and continued statin therapy after 
surgery. A total of two hundred and twenty four POIC occurred. Best-fit logistic 
regression models demonstrated that ASA classification, length of operation, and 
emergent status of case were associated with an increase in POIC. Patients receiving 
statins, when adjusted for ASA classification, length of operation, and case emergency, 
did not have a reduced risk of POIC, with an AOR 0.978 (95% CI 0.58 – 1.63, p = 0.93). 
Statin use was, however, associated with a reduction in 30 day postoperative mortality 
(OR 0.45; 95% CI 0.23 – 0.87, p = 0.019).  
Conclusion: 
Preoperative statin therapy reduces the risk of 30 day mortality, but its effect on reducing 
POIC after general surgery remains to be proven. Further research is needed to evaluate 
the role of preoperative statin therapy and its pleiotropic effects in surgical patients. 
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Section 4: Introduction 
Infections and Surgery 
Postoperative complications remain a dreaded result of surgical procedures.  Such 
complications increase morbidity of patients, increase utilization of medical resources 
and increase the overall cost of delivering health care 1, 2.  Researchers have found that 
infectious, cardiovascular, respiratory, and thromboembolic complications could account 
for an increase of upwards of $11,626 or more in the health care expenditure of a surgical 
patient 3.  The prevalence of infectious complications in surgery has been reported to be 
around 13.3%, with surgical site infections (SSI) accounting for 2-5% 4, 5.  In 2005, 45 
million surgical operations were performed in the U.S. alone; extrapolated cost, 
morbidity, and allocation of resources toward postoperative complications are staggering 
6.  Much attention has been dedicated to the reduction and elimination of postoperative 
complications 4, 7-13.  Efforts to reduce surgical infections have included surgical 
checklists, a Surgical Apgar Score, prophylactic antibiotic treatment, and controlling 
glucose levels both acutely and chronically 9, 10, 13-16. 
 
Recent literature has suggested that 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
inhibitors (HMG CoA reductase inhibitors), commonly known as statins, may have a role 
in mitigating sepsis and baceteremia in patients in intensive care units and have a role in 
decreasing mortality in surgical patients undergoing cardiac surgery 17-29.  Researchers 
have theorized that the cholesterol-independent effects of statins are the result of blocking 
other products in the mevalonte pathway, but clinically the results are poorly understood. 
The use of statins for these purposes are in stark contrast to their initial hypothesized 
mechanism of action and clinical benefit.  
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3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (Statins) 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are a 
class of medications that block low density lipoprotein (LDL) cholesterol biosynthesis by 
inhibiting conversion of HMG-CoA to mevalonate 30, 31.  Inhibiting this rate-limiting 
step in LDL cholesterol biosynthesis results in an overall decrease in circulating serum 
cholesterol levels.  The decreased concentrations of mevalonate cause a negative 
feedback loop that drives the increase production of LDL cholesterol receptors (LDLr) in 
hepatocytes.  Statins, therefore, induce LDLr mRNA production in the cell that leads to 
up-regulation of LDLr on the surface of the cell 32.  The decreased availability of 
cholesterol in the cell drives the extraction circulating serum LDL cholesterol.  This leads 
to a decrease of serum LDL cholesterol, the clinically apparent effect of statin therapy 
33-36. 
 
In addition to blocking mevalonic acid, statins block all down stream products in the 
cholesterol biosynthesis pathway.  The main products blocked other than mevalonate are 
isoprenylated protein intermediates.  Isoprenoid intermediates, including 
farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), have a role in 
the post-translational modification of several key proteins, which allows the proteins the 
ability of covalent attachment, subcellular localization, and intracellular trafficking in the 
cell 19.  Both FPP and GGPP have important effects on GTP-binding proteins, in 
particular the subgroup of the Ras superfamily: Rho GTPases.  Rho GTPases, including 
RhoA, RhoB, Rac1, Rac2, Cdc42Hs, and TC10, have important roles in membrane 
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trafficking, transcriptional regulation, cell growth 37.  In particular, FPP interacts with 
the Ras protein while GGPP interacts with the Rho protein.  Since statins inhibit the 
formation of both FPP and GGPP, isoprenylation of Ras and Rho does not happen as 
readily, resulting in the inactive form of both building in the cell’s cytoplasm 17.  
Inhibition of Rho-GTPases by statins was largely viewed, based on in vitro studies, to be 
responsible for their pleiotropic effects.  Such effects include: decreasing platelet 
activation, anti-thrombotic properties, increasing plaque stability, decreasing vascular 
inflammation, decreasing smooth muscle cell hypertrophy and proliferation, decreasing 
endothelial dysfunction, and decreasing vasoconstriction 19. 
 
In addition to these pleiotropic effects, statins have other important effects as well.  There 
are a few mechanisms believed to relate directly to the ability to modulate the immune 
system.  These effects include modulating the interaction and response of immune cells, 
reducing inflammatory cytokines by suppressing their gene expression within the cell, 
and antioxidant effects. 
 
Interactions between Statins and Various Immune Cells 
Statins have been reported in vitro to bind to and inhibit integrin leukocyte function 
antigen-1 (LFA-1) 38, 39.  By doing so, LFA-1 is unable to bind to intracellular adhesion 
molecule 1 (ICAM-1), which has pathways related to T-cell proliferation among other 
important roles in cell signaling and migration.  It is important to note that this was 
achieved at much higher than clinically prescribed levels 38.  Regardless, this has many 
researchers wondering about its effect on patients on statin therapy.  Statins also interact 
 9 
with T-cells by altering their activity.  It has been shown in vitro that statins modify T-
cell activity directly by inhibiting MHC class II expression induced by interferon gamma 
(IFN-γ) 40.  In addition, statins have been shown to reduce the inflammatory response of 
macrophages and endothelial cells infected with c. pneumoniae mainly through altering 
cell signaling in cytokine production 41 
 
Statins, Cytokine Production, and Cellular Signaling 
Statins affect several protein kinase cascades because of their ability to decrease levels of 
FPP and GGPP.  While multiple pathways exist to activate these protein kinases, several 
of the Rho and Ras GTPases (e.g. RhoA, Rac1, Cdc42Hs) relate to FPP and GGPP and 
are subsequently blocked by statin’s blockage of HMG CoA reductase 42.  One important 
cascade that is blocked involves nuclear factor-kappa B (NF-κB). NF-κB has an 
important role in the production of cytokines in response to lipopolysacchride (LPS) and 
bacterial presence.  It has been documented that LPS interacts with CD14, causing a 
signal transduction via Toll-like receptor-4 (TLR-4), ultimately activating NF-κB 43.  
Once NF-κB is activated, it enters the nucleus and produces cytokines that lead to T-cell 
maturation and proliferation.  NF-κB exists in the cytoplasm, often in its inhibited form 
of iκB.  When phosphorylated, iκB releases NF-κB and allows NF-κB to travel to the 
nucleus to induce the expression of various cytokines, chemokines, and adhesion 
molecules.  In vitro studies have demonstrated that statins upregulate iκB protein levels, 
and therefore reduce the ability of NF-κB to express cytokines 44-46.  In addition, statins 
inhibit the binding of nuclear proteins to both NFκB and activator protein-1 (AP1) 44.  
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The clinical implications of these effects are not known, but could relate to statins impact 
on atherosclerosis as well sepsis. 
 
Furthermore, statins have a profound impact on other cellular proteins.  Statin treatment 
of monocytes in vitro leads to activation of peroxisome proliferator-activated receptor 
gamma (PPAR) while inhibiting production of tumor necrosis factor alpha (TNF-α) 47.  
PPAR is an important nuclear receptor involved in macrophage function and 
development.  TNF-α is an important cytokine involved in activation of NF-κB and 
MAPK signaling pathways as well as other cytokine production, and even apoptosis.  
Statins have also shown to decrease interleukin-1 (IL-1) and interleukin-6 (IL-6) 48.  In 
addition, there is evidence to support the reduction in levels of monocyte chemoattractant 
protein-1 (MCP-1) and interleukin-8 (IL-8) during infection by statin therapy 41.  Lastly, 
C-reactive protein (CRP), an acute phase reactant, has also been repeatedly demonstrated 
to be lower in the presence of statins both in vitro and in vivo 45, 46, 49.  By reducing 
these levels of cytokines, it is believed that statins may alter the course of sepsis, severe 
sepsis, and multiple organ dysfunction syndrome.  
 
Antioxidant effects of Statins 
Statins may increase the antioxidant effects of endothelial cells and thus have important 
implications in interacting with the immune system.  In a study that sought to evaluate the 
role of statin treatment on endothelial function, Landemesser et al randomized patients 
into a simvastatin and a ezetimibe treatment group for 4 weeks of treatment 50.  A variety 
of measurements were taken, including endothelium-bound extracellular superoxide 
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dismutase (ecSOD).  Interestingly, simvastatin improved endothelial function through an 
increased ecSOD and reduced vascular oxidative stress, presumed by the reduced impact 
the antioxidant vitamin C had on endothelium-dependent vasodilation after simvastatin 
50.  In addition to an increase in ecSOD, it is felt that statins also increase 
hemeoxygenase-1 (HO-1).  In a study of rosuvastatin on cultured endothelial cells, free 
radial formation was inhibited on the endothelial cells treated with the statin 51.  In 
addition, rosuvastatin was found to induce HO-1 measured by an increase in mRNA and 
protein levels 51.  Statins’ anti-inflammatory and anti-oxidant effects, as well as its 
ability to lower LDL cholesterol, have direct implications towards its treatment of 
endothelial dysfunction, the basis of atherosclerosis.  
 
Atherosclerosis 
Elevated serum cholesterol levels play an integral role in the development of 
atherosclerosis.  Atherosclerosis is an inflammatory “response-to-injury” condition that 
affects the medium to large arteries in individuals predisposed to endothelial dysfunction 
52.  Such endothelial dysfunction is found in association with hypertension, diabetes 
mellitus, cigarette smoking, and high serum levels of LDL 52.  Atherosclerosis is 
initiated by damage to the endothelial layer, often the one-cell thick intima, which leads 
to an inflammatory response via the accumulation of monocytes and T-cells that release 
various cytokines and chemokines 52.  A fatty streak is soon formed, created by foam 
cells (monocytes and macrophages filled with lipid) as the disease progresses 52-54.  In 
advanced disease, a fibrous cap, formed by various growth factors, covers the lesion 
filled with leukocytes, LDL cholesterol, and other components of the fatty streak 52-54.   
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In time, the fibrous plaque may ulcerate or rupture, and leads to thrombus formation 
and/or complete occlusion of the artery from platelet aggregation, leading to ischemia 52.   
Clinically, this is seen as coronary artery disease (CAD) and myocardial infarctions (MI), 
cerebral vascular disease and stroke, and peripheral vascular disease and ischemic limb.  
 
Statin Clinical Trials and Lipid Lowering Properties 
Decreasing circulating serum cholesterol has long been both a treatment and a prevention 
strategy for improving health, particularly for preventing CAD.  The Framingham Study 
made famous the relationship between serum cholesterol, risk of CHD, and premature 
death from CHD 55-57.  In 1984, the Lipid Research Clinic Coronary Primary Prevention 
Trial (LRC-CPPT) concluded that a reduction in the total cholesterol level (via lowering 
LDL cholesterol) diminished the incidence of coronary heart disease (CHD) morbidity 
and mortality in patients 35, 58.  The LRC-CPPT was a large, multi-center, randomized, 
double blind study that included 3,806 asymptomatic, middle-aged men with primary 
hypercholesterolemia 58.  The study had two treatment arms, cholestryamine versus 
placebo, and used CHD, death, or non-fatal myocardial infarction (MI) as primary 
endpoints.  In cholestryamine-treated group, a 19% reduction in risk (p < 0.05) was found 
that corresponded with a decrease in the patient’s plasma total and LDL cholesterol levels 
35.  The study concluded that the lipid lowering benefits of the cholestryamine aided in 
this reduction of risk. 
 
In the POSCH or the Program on the Surgical Control of the Hyperlipidemias in 1990, 
surgeons performed partial ileal bypass procedures on patients in an attempt to lower 
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cholesterol 59.  The study, a randomized clinical trial featuring 838 patients who had 
evidence of CHD (through documented prior MI), showed a decrease in LDL, increase in 
high-density lipoprotein (HDL) cholesterol, and overall reduction in morbidity and 
mortality from CHD 59.  The study concluded that while partial ileal bypass needed to be 
studied more, there was strong evidence to support lipid modification in the reduction of 
morbidity and mortality of CHD 59.  The measurement of circulating serum cholesterol 
levels was the focus of the National Cholesterol Education Program as a high-risk 
intervention strategy to combat hypercholesterolemia and reduce the risk of CAD 36, 60, 
61.  The mounting research yielded the Lipid Hypothesis, which suggested that by 
decreasing serum cholesterol, one could expect a reduction in risk of developing CHD.  
Lipid lowering medications, including statins, were therefore studied extensively for their 
direct role of inhibiting cholesterol biosynthesis and reducing circulating serum 
cholesterol in patients at risk for developing CAD. 
 
Several clinical trials have studied the role of statins in cardiovascular disease 33, 34, 62-
66.  These trials often demonstrate the beneficial effects that statins have on lowering 
serum cholesterol and reducing risk of CHD.  In the Scandinavian Simvastatin Survival 
Study (4S), a double-blind randomized-controlled trial (simvastatin versus placebo) 
featuring 4,444 patients with CHD, simvastatin decreased total cholesterol and LDL 
cholesterol by 25% and 35% respectively 62.  In addition, the study showed that there 
was a slightly greater 6-year probability of survival (87.6% for placebo versus 91.3% for 
simvastatin) making simvastin safe for long-term use and beneficial in patients with CHD 
62.  
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In 1996, the Cholesterol and Recurrent Events Trial (CARE) investigators published a 
study that examined the role of pravastatin on coronary events in patients with previous 
history of MI.  The study was a 5-year double-blind randomized controlled trial with a 
total of 4,159 patients and found that statins were a benefit to patients with underlying 
CAD who had average cholesterol levels.  The study found a 24% risk reduction between 
the pravastatin group and the placebo group 63. Likewise, the Long-Term Intervention 
with Pravastatin in Ischemic Disease (LIPID) Study Group performed a double-blind, 
randomized controlled trial comparing the effects of pravastatin versus placebo.  The 
9,014 patients ranged in age from 31 to 75 years, had documented CHD (either history of 
myocardial infarction or unstable angina), and total serum cholesterol between 155 to 271 
mg per deciliter 34.  In these patients, pravastatin reduced the risk of MI, stroke, coronary 
revascularization, mortality from CHD, and overall mortality 34.  These studies provided 
sufficient evidence to support the use of statins to safely reduce serum cholesterol levels 
for the treatment of CHD with the Lipid Hypothesis the basis of statin therapy.  
 
Evidence of Statins Beyond Lipid Lowering 
The lipid lowering benefits of statins were demonstrated in vivo in the 4S, CARE, and 
LIPID trials. However, the only evidence of the pleiotropic mechanisms of statins was in 
vitro; it was hard to extrapolate these in vitro results to determine a plausible effect in 
vivo. Two very important studies noted the pleiotropic effects of statin therapy.  They 
gave credence to a realistic possibility of a clinically apparent alternative mechanism of 
statin therapy. The first was the West of Scotland Coronary Prevention (WOSCOP).  The 
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WOSCOP, whose primary aim was to demonstrate the ability of pravastatin to reduce 
morbidity and mortality from CHD in men who had moderate hypercholesterolemia, 
showed that several patients benefited from treatment beyond LDL reduction 33.  The 
study compared the pravastatin versus placebo groups and used a Cox regression model 
to examine baseline lipid levels, treatment lipid levels, cardiovascular events, and 
subsequent risk reduction in those receiving pravastatin. In the analysis, there was a 
benefit (noted by a lower CHD risk) of pravastatin over placebo found in a quintile of the 
patients with the same LDL level, resulting in the conclusion that LDL reduction alone 
could not account for the benefit 33.  It was felt that there were benefits to the pravastatin 
beyond decreasing serum LDL. Similarly, the previously mentioned CARE study showed 
a sub-group analysis that alluded to the benefits of statins in patients where serum 
cholesterol reduction could not account for the benefit.  In this study, it was found that 
when pravastatin and placebo groups with similar serum cholesterol levels were 
compared, the pravastatin group had significantly lower risk of CHD 63.  Again, a 
decrease in serum cholesterol alone could not account for the improved benefit. 
 
In both the WOSCOP and CARE studies, sub-group analysis demonstrated a benefit to 
statin therapy in the absence of significant reduction of serum cholesterol.  These 
cholesterol-independent effects have also come to light when comparing the amount of 
time it takes for a treatment to have a benefit.  In two non-statin in vivo studies, the 
POSCH and the LRC-CPPT, it took greater than 7 years for a benefit of treatment 
whereas it takes around 5 years in the statin groups 17, 35, 59.  In fact, the Pravastatin or 
Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 
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22 or PROVE-IT TIMI 22, researchers observed a benefit of both standard therapy (40 
mg pravastatin) and intensive therapy (80 mg atorvastatin) in patients presenting with 
acute coronary syndrome when treatment was started within 10 days of hospitalization 
67.  Furthermore, statin trials have a greater overall cardiovascular benefit compared to 
the non-statin trials 17.  
 
Other trials have also alluded to the dramatic benefit of statins outside of their ability to 
lower serum cholesterol.  One small study sought to compare simvasatin with ezetimibe, 
a cholesterol absorption inhibitor in 20 patients with chronic heart failure 50.  The 
researchers hypothesized that both simvastatin and ezetimibe would lower LDL 
cholesterol, but have differing effects on endothelial function over a 4 week period 50.  
The study  found that simvastatin improved endothelial function when compared to 
ezetimibe even though both simvastatin and ezetimibe had similar reduction in LDL 
cholesterol 50.  A similar study also compared atorvastatin and ezetimibe in a group of 
patients with stable CAD, finding similar results in comparable reduction in LDL 
cholesterol but improved endothelial function in atorvastatin 68.  The evidence from 
these trials and in vivo studies joined the mounting evidence from in vitro studies on the 
pleiotropic effects of statins.  
 
Statins and Infections 
With knowledge and clear evidence of the pleiotropic effects of statins in cardiovascular 
disease, several researchers decided to test the hypothesis of statins’ abilities to affect the 
immune system. Therefore, several in vivo studies have looked at the role of statins in 
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patients with sepsis 21, 27, 69-72.  The largest of these studies was performed in Canada, 
taking advantage of the administrative records and universal coverage. Hackam et al 
performed a 5-year population-based cohort analysis on nearly 69,168 patients with 
cardiovascular disease that had been hospitalized for acute coronary syndrome, stroke, or 
revascularization that had survived at least 90 days after discharge 70. Half of the patients 
received a statin (34,584) while the other half did not. The study showed that the 
incidence of sepsis was lower in patients receiving statins, at roughly 71.2 events per 
10,000 person-years for the statin group versus 88.0 events per 10,000 person-years for 
patients not receiving statins (p=0.00003) 70. This equated to univariate hazard ratio 
(HR) of 0.81 (95% CI of 0.72 – 0.91) and a multivariate (adjusted for demographics, risk 
factors for sepsis, and other co-morbidities) HR of 0.81 (95% confidence interval of 0.72 
– 0.90) 70. The study also found further evidence that those patients receiving statins also 
had a decreased incident of fatal sepsis 70.  
 
In 2001, Liappis et al studied the impact of statins on mortality of patients with bactermia 
in the mostly male population of their VAMC. In this retrospective review of 388 
infections secondary to aerobic gram-negative bacilli and staphylococcus aureus, the 
investigators found an overall hospital mortality rate of 6% in patients receiving statins 
compared to 28% for patients not receiving statins (P = 0.002) 69. The study found an 
attributable morality rate of 3% for patients on statins compared to 20% for patients not 
receiving statins (p = 0.010) 69. Conclusions about the effects of specific statins were not 
possible because of the low numbers of patients. The study proposed that a statin’s 
beneficial effect on patients with bactermia was the ability to interrupt the 
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proinflammatory cytokine release related to infection. However, with such low numbers 
of patients, even though they are statistically significant, it may be difficult to draw major 
conclusions about the use of statins in patients with infections.  
 
Almong et al performed a prospective observational cohort study, published in 2004, 
exploring the relationship between statins and sepsis. In this study, it was hypothesized 
that preadmission statin use will have protective effects against severe sepsis and 
therefore patients receiving statins would develop sepsis less frequently than those not 
receiving statin therapy 21. Patients greater than 40 years old, non-pregnant, without HIV 
or malignancy, and on statin therapy for greater than one month admitted to the ICU with 
documented acute bacterial infection were enrolled prospectively. The acute bacterial 
infections included pneumonia, urinary tract infection, and cellulitis. The study used the 
definition of severe sepsis and sepsis-induced organ dysfunction set forth by the Protein 
C Worldwide Evaluation in Severe Sepsis (PROWESS) investigators 21. Ultimately, 361 
patients were included in the study, 82 patients in the statin group versus 279 patients in 
the non-statin group 21.  One hundred and seventy seven patients or 49% of the patients 
admitted to the ICU were diagnosed with pneumonia, 38.8% had urinary tract infection, 
and 12.2% had cellulitis 21. The study found that the rate of severe sepsis in the group 
not receiving statins was 19% (95% CI 14.4% to 23.6%), whereas the rate in the statin 
group was 2.4% (95% CI 0% to 5.7%) 21. There was also a decreased 28 day mortality 
rate for the patients receiving statins (3.7% versus 8.6%) (p = 0.14). A logistic regression 
analysis was also performed to adjust for variables identified in the univariate analysis to 
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be associated with severe sepsis.  Results showed that statin treatment, serum albumin, 
and APACHE II score, were all associated with a reduction in severe sepsis 21. 
 
Mortensen et al performed a retrospective study to explore the role of pre-admission 
statin use on 30 day mortality for patients hospitalized for pneumonia 27. The study took 
place at two academic tertiary care hospitals and included patients admitted with 
pneumonia, evident by both chest x-ray and by ICD-9 diagnosis of pneumonia on 
discharge. A pneumonia severity index score was calculated for each of the patients 
(based on demographic, co-morbid illness, physical examination findings, and laboratory 
and radiographic findings). Data were included from 787 patients, of which 52% were 
low risk (pneumonia severity index class between I and III) 34% were moderate risk, 
(pneumonia severity index class of IV) and 14% were high risk (pneumonia severity 
index class of V) 27.  Of the enrolled patients, 110 were on statins. The 30 day and 90 
mortality rates were 9.2% and 13.6% respectively. In univariate analysis several 
components of the pneumonia severity index were statistically associated with 30 
mortality, including demographics (age and nursing home residency), past medical 
history (heart failure, stroke, malignancy, diabetes,) and clinical parameters (blood 
pressure, elevated glucose).  In multivariable regression analysis, statin use was found to 
decrease the 30 day morality rate, with an AOR 0.36 (95% CI 0.14-0.92) 27.  
  
In a similar study done prospectively, Chalmers et al studied the role of statins in patients 
with community-acquired pneumonia.  This prospective observational study sought to 
characterize the effects of other medications the enrolled patients were taking, by 
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collecting information about ACE inhibitors, beta-blockers, and aspirin as well as statin 
24.  This was the first study designed to elucidate the effects of other cardiovascular 
medications with statins on 30 day mortality rate and incidence of pneumonia. The 
outcomes in this study were 30 day mortality, mechanical ventilation or pharmacologic 
(inotropic) support, and progression of disease to a more complicated pneumonia, such as 
effusion or empyema.  Laboratory data, including C-reactive protein levels were 
collected and a pneumonia severity index (PSI) was calculated for each patient.  In all, 
1007 patients with community-acquired pneumonia were enrolled.  Multivariate logistic 
regression revealed that statin therapy was associated with a reduced 30 day mortality  
(AOR 0.46; 95% CI 0.25 – 0.85, p = 0.01) 24.  Age over six five years old, pneumonia 
severity greater than or equal to 4, chronic cardiac failure, and beta-blocker use were all 
associated with increased 30-day mortality.  Statin use was also associated with a reduced 
incidence of complications from pneumonia (AOR 0.44; 95% CI 0.25 – 0.79, p = 0.006), 
while PSI greater than or equal to 4 was indicative of increased risk of developing a 
complication (AOR 1.49; 95% CI 1.16 – 1.83, p = 0.001) 24.  Although statin users 
tended to have the highest PSI compared to patients not prescribed any cardiovascular 
medications, admission C-reactive protein levels were significantly lower for patients 
receiving statins compared to patients receiving other cardiovascular medications and to 
patients not receiving any cardiovascular medications.  C-Reactive protein levels at day 
four for patients receiving statins tended to be lower as well.  The study concluded that 
there was no benefit from aspirin, ACE inhibitors, or angiotensin II receptor antagonists 
in patients admitted for the treatment of community-acquired pneumonia.  C-reactive 
protein levels were reduced in patients treated with statins, confirming a reduction in 
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systemic inflammation through statin treatment.  Lastly, a reduction in 30 day mortality 
and complicated pneumonia was seen in association with statin use.   
 
In a similar study from Denmark, Thomsen et al conducted a population-based cohort 
study of 29,900 adults hospitalized with pneumonia over a seven-year period.  These 
investigators sought to study the association between preadmission use of statins in 
patients hospitalized for pneumonia, the risk of nosocomial bacteremia and pneumonia 
complications, and the 30 and 90 day mortality 73.  Current statin users were identified as 
any patient that filled at least one prescription within 125 days of admission (chosen 
because of a compliance rate of 80% to 100% in the Danish patient population).  Those 
with at least one prescription filled prior to 125 days of admission were grouped as 
former statin users.  Other demographic and clinical data were also extracted from the 
hospital database, including age, sex, co-morbidities, concurrent medication usage, and 
severity of pneumonia (based on the Charlson Comorbidity Index score) 73.  The primary 
outcome measure was death (any cause) within 30 days and 90 days after admission, with 
secondary outcomes being bacteremia and pulmonary complications, namely pleural 
effusion, lung abscess, empyema, or adult respiratory distress syndrome (ARDS).  In the 
final analysis, statin users were more likely to be older, have more co-morbidities (2-5 
times likely to have had a MI, heart failure, vascular disease, or diabetes) and therefore 
on average have  higher co-morbidity index scores. Yet, the 30-day mortality rate for 
statin users was 10.3%, compared to 15.7% for non-statin users (the crude mortality RR 
was 0.63; 95% CI 0.54 – 0.75, p < 0.01) 73.  Likewise, the 90-day mortality rate for the 
statin users was also lower than the non-statin users at 16.8% compared to 22.4% (the 
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crude morality RR was 0.72; 95% CI 0.63 – 0.82, p < 0.01) 73.  The study found no 
association between mortality and preadmission use of ACE inhibitors or low-dose 
aspirin, but a slight decreased mortality was found in association with beta-blockers.  The 
cumulative incidence of pulmonary complications was 1.5% for statin users and 2.1% of 
non-statin users.  This yielded a slight reduction in the risk of pulmonary complications, 
although it was not statistically significant with an adjusted RR of 0.69 (95% CI 0.42 – 
1.14) 73.  
 
Another retrospective study, performed by Martin et al, explored the association between 
statins, severe sepsis, and organ dysfunction amongst patients with severe sepsis 74. 
Using data from patients admitted over a 1 year time period, the study used admission 
ICD-9 codes for septicemia, unspecified septicemia, systemic inflammatory response 
syndrome with and without organ dysfunction for inclusion criteria.  Pharmacy records 
and admission history and physical examination results from the patient’s electronic 
medical records were used to confirm if the patients were taking statins before and during 
admission.  Exclusion criteria included age younger than 40 years, transfer during 
medical care from another institution, statins use during admission but not before, 
malignancy, HIV positive status, neutropenia, and immunosuppressant drug treatment. 
The primary endpoint was severe sepsis, defined by the American College of Chest 
Physicians and the Society of Critical Care Medicine (ACCP-SCCM) as sepsis with at 
least one organ dysfunction such as cardiovascular, renal, pulmonary, hematologic, or 
metabolic. The secondary end points were 30 day in-hospital mortality rate and the rates 
of cardiovascular, renal, pulmonary, hematologic, and metabolic organ dysfunction.  In 
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the end, only 53 patients met all eligibility criteria, 16 in the statin group and 37 in the 
non-statin group.  The rate of severe sepsis in the statin group was 56% compared to a 
rate of 86% in the non-statin group, showing that statins were associated with a 30% 
reduction in the rate of severe sepsis 74.  There was also a statistically significant 
difference in the in-hospital mortality rate, with the statin group having a rate of 38% and 
the non-statin group having a rate of 49% (p = 0.33). In sub-group analysis, the rate of 
cardiovascular dysfunction was significantly lower in the statin group versus the non-
statin group (38% versus 73%, p <0.02) 74.  The study concluded that statins’ ability to 
maintain vascular integrity was responsible for the differences in rates of cardiovascular 
dysfunction. While the difference in mortality rate among statin users and non-users was 
not significant, the authors attributed this finding to the small sample size. 
 
Kruger et al. conducted a retrospective cohort analysis to find the association between 
statins and deaths due to bacteremia.  Data were collected on 438 patients over age 18 
years old that were admitted for bacteremia over a four-year period 72.  Clinical and 
demographic information included: age, ICU admission, co-morbidities (hypertension, 
diabetes, heart failure,) and medications (ACE inhibitors, aspirin, beta-blockers). 
Baseline characteristics associated with hospital mortality from bacteremia were 
identified and included age, immunosuppression, and e. coli infection.  Sixty-six patients 
were receiving statins prior to admission while 372 patients did not receive statins; 10 
patients stopped statin therapy after being admitted, while 56 continue statin therapy. 
Results showed that statins were associated with reduced hospital mortality, with an OR 
of 0.39 (95% CI 0.17 – 0.91, p = 0.029) 72.  Deaths attributable to bacteremia were also 
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reduced in patients on preadmission statins that continued therapy throughout 
hospitalization (OR 0.29; 95% CI 0.10 – 0.86, p = 0.025) 72.  Likewise, it was also 
associated with reduced mortality (OR of 0.06; 95% CI 0.01 – 0.44, p = 0.0056) 72. 
Mortality rates were highest in patients who did not have preadmission statins during the 
hospital stay. 
 
In an effort to further characterize the effect of statins and their ability to reduce 
inflammation, Schmidt et al performed a retrospective cohort study evaluating the impact 
of statins in patients with multiple organ dysfunction syndrome (MODS) 75.  The 
hypothesis, predicated on the ability of statins to reduce incidence of sepsis and 
septicemia, was that preadmission statin treatment would have a survival benefit for 
MODS patients.  In all, 40 MODS patients using statins were age and sex matched with 
80 MODS patients not receiving statins. Inclusion criteria for the patients in the study 
were admission to ICU and APACHE II score greater than or equal to 20 at admission. 
There was no difference in baseline characteristics (age, APACHE II, Sequential Organ 
Failure Assessment or SOFA) between the groups.  In the end, the 28 day mortality rate 
was 33% for the statin treated group compared to 53% for the non-statin group.  A Cox 
proportional hazard analysis showed a HR of 0.53 (95% CI 0.29 to 0.99, p = 0.04) 75. 
The study concluded that statin therapy decreases 28 day mortality rate for MODS 
patients with equally severe disease. 
 
Statins and the Surgical Patient 
 25 
Studies have shown beneficial effects of preoperative statins use on the reduction of 
morbidity and mortality of cardiac and vascular surgery patients postoperatively 20, 76-
85.  Recently, two meta-analysis studies have attempted to consolidate the findings for 
cardiac, vascular, and non-cardiac surgery 86, 87.  Hindler et al performed a meta-
analysis of the studies exploring the role of preoperative statin use and postoperative 
outcomes.  The study conducted a thorough literature review of MEDLINE, EMBASE, 
the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systemic 
Reviews, the American College of Physicians Journal Club, and the Database of 
Abstracts of Reviews of Effects (as well as several abstracts from conferences and 
scientific meetings), to identify randomized, prospective clinical trial and retrospective 
observational studies published from 1977 to 2005 on the topic 87.  Publications that 
detailed preoperative statin use and surgical outcomes were included.  Outcomes 
included, MI, cardiac arrhythmia, stroke, and 30-day mortality.  Each qualified study was 
placed into one of three groups: cardiac, vascular, or non-cardiovascular surgery.  The 
quality of each study was then evaluated and rated based on randomization of 
participants, randomization of procedures, control group, and monitoring treatment 
fidelity.  Of the 1,100 abstracts evaluated, there were 15 total publications that met all 
inclusion criteria: seven articles about cardiac surgery and statins, seven articles about 
vascular surgery and statins, and one article for non-cardiac surgery.  
 
In the meta-analysis, the study found that postoperative mortality was significantly lower 
in patients receiving statins (1.9% versus 3.1%, p < 0.0001 for n = 12,752 in 7 studies) 
87.  Interestingly, there was an increase in the incidence of MI in those patients receiving 
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statins (4.6% versus 3.6%, p = 0.02 for n = 7,615 in 5 studies) 87.  There was no 
significant difference between the two groups for cardiac arrhythmia or stroke (22.3% 
versus 23.0%, p = 0.99 for n = 3,294 in 3 studies and 2.7% versus 3.2%, p = 0.26 for n = 
4,872 in 3 studies, respectively) 87.  
 
The meta-analysis for patients undergoing vascular surgery yielded comparable results 
for mortality and cardiac arrhythmia, but not for MI and stroke.  Postoperative mortality 
was reduced in patients receiving statins (1.7% versus 6.1%, p < 0.0001 for n = 5,373 in 
7 studies) 87.  Unlike the cardiac surgery meta-analysis, statin use was associated with a 
reduction in the incidence of MI (2.7% versus 6.2%, p = 0.001 for n = 2,862 in 5 studies) 
and stroke (2.0% versus 3.3%, p = 0.049 for n = 2,749 in 4 studies) in vascular surgery 
patients 87.  There was no significant difference in the rate of cardiac arrhythmia 
amongst vascular surgery patients receiving statins (11.4% versus 11.1%, p = 1.0 for n = 
329 in 2 studies) 87. 
 
When evaluating all types of surgical procedures (which included cardiac, vascular, and 
thoracic surgeries), the researchers found a 1.0% absolute reduction of 30 day 
postoperative mortality for statin users (2.2% versus 3.2%, p < 0.0001) 87.  They also 
found a 44% reduction in the odds of 30 day mortality in patients undergoing surgical 
procedures on statin therapy (OR 0.56; 95% CI 0.43 – 0.71).  The compilation of this data 
demonstrates the cumulative evidence of statins and their association of reducing the 30 
day mortality after cardiac, vascular, and thoracic surgery.  While there were flaws and 
weaknesses to this study, including varying methodologies in the analyzed studies, the 
 27 
inclusion of mostly retrospective observational studies, the weight of a few large studies 
possibly skewing the data, and an inability to control for confounders, the study 
concluded that statins were associated with a survival benefit in surgical patients.  
 
The other meta-analysis, performed by Liakopoulos et al, focused on the magnitude of 
cardiac surgery studies and their relationship with preoperative statin use.  MEDLINE, 
EMBASE and the Cochrane Library (including the Cochrane Database of Systemic 
Reviews, Database of Abstracts of Reviews and Effects, and The Cochrane Central 
Register of Controlled Trials) as well as abstracts and oral presentations from several 
scientific meetings for retrospective observational studies and RCT were searched 86. 
The study extracted information on 30 day mortality, MI, atrial fibrillation, stroke, and 
renal failure.  Each publication was evaluated for their quality, clinical outcomes, and 
type of surgery performed.  In total, 31,201 cardiac surgery patients were included from 
19 publications from 1999 to 2007 (3 were RCT, 3 were prospective observational, and 
13 were retrospective observational) 86.  Seventeen thousand, two hundred and one 
patients were on preoperative statin therapy, with the remaining 14,524 not on statins.  
 
The meta-analysis showed a reduced incidence of short-term mortality in cardiac surgery 
patients receiving statins before cardiac surgery compared to patients not receiving statins 
(2.2% versus 3.7%, p < 0.0001), with an absolute risk reduction of 1.5% (from 15 studies 
with an n = 28,517) 86.  This equated to an OR of 0.57 (95% CI 0.49 – 0.67, p < 0.0001), 
or a 43% reduction in the risk of 30 day mortality in patients receiving statins.  However, 
no significant difference was found in the reduction in incidence of MI between the two 
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groups (4.2% versus 3.9%, p = 0.373 from 10 studies with an n = 14,330) 86.  This was 
equivalent to an OR of 1.11 (95% CI 0.93 – 1.33, p = 0.25).  In 7 studies with 7,643 
patients there was  an overall incidence rate of 26.9% for postoperative atrial fibrillation, 
with patients receiving statins having an incidence rate of 24.9% compared to the non-
statin group with an incidence rate of 29.2% (p < 0.0001)  86.  This was the equivalent of 
a 4.3% absolute risk reduction and a 33% reduction in the odds of atrial fibrillation for 
patients receiving statins (with an OR of 0.67; 95% CI 0.51 – 0.88, p = 0.004).  Likewise, 
the study found a lower rate of stroke (2.1% versus 2.9%, p = 0.001) in patients on statin 
therapy 86.  This was equivalent to a 26% reduction in the odds of stroke for cardiac 
surgery patients receiving statins before surgery (OR 0.74; 95% CI 0.60 – 0.91, p = 0.004 
from 7 studies with an n = 16,390).  Lastly, the study did not find a statistically 
significant reduction of the incident of renal failure.  Among the 5 studies analyzed (with 
a total of 6,408 patients), the incidence of renal failure amongst statins and non-statin 
patients was 3.9% and 4.5% respectively (p = 0.275), with the OR being 0.78 (95% CI 
0.46 – 1.31, p = 0.34).  Since it was not statistically significant, the study did not believe 
that the evidence was sufficient to suggest statins protect against renal failure 86.  
However, this was in contradiction to other studies that have shown renal protective 
effects of statins 85.  
 
From these meta-analyses, there was clear evidence of the association between statins 
and a reduced risk of all cause short-term mortality and a decreased incidence and risk of 
cardiovascular postoperative. Both the Hindler and the Liakopoulos studies found 
reduction in absolute risk of all cause short-term mortality. In particular, the Hindler 
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study was able to demonstrate the effect of statins in both cardiac and non-cardiac 
surgeries, including vascular surgery and thoracic surgery. 
 
Statins and Surgical Infections 
Only one study has looked at preoperative statin use and postoperative infectious 
complications 82. Coleman et al performed a retrospective observational study on 
patients undergoing coronary artery bypass surgery (CABG), cardiac valve surgery, or 
both. Postoperative infectious complications that were followed included: pneumonia, 
bacteremia, urinary tract infection, leg vein harvest site infection, tracheotomy site 
infection, prolonged length of stay, and death. The primary endpoint was the combined 
incidence of any infectious outcome, while secondary endpoints were the incidence of 
individual infectious complications, death, and prolonged hospitalization (greater than 6 
days). Looking back on records from January 2004 through August 2006, the researchers 
identified 1,934 patients that were eligible to be enrolled in their analysis, of which 1,248 
patients received preadmission statins while 686 did not receive any statin therapy. There 
were some variations between the statin therapy patients and the non-statin therapy 
patients with respect to demographic, preoperative, and perioperative variables. For 
example, statin users were more likely to have a history of diabetes, chronic obstructive 
pulmonary disease high cholesterol, and to be smokers than patients not on preoperative 
statin therapy.  
 
The researchers found that a total of 151 patients developed at least one postoperative 
infectious complication. Using a multivariable logistic regression to control for potential 
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confounders in the preoperative and perioperative variables, a 33% reduction in the risk 
of developing a postoperative infectious complication of any kind (AOR 0.67; 95% CI 
0.46 – 0.99, p = 0.04 for n = 151) was found. Evaluation specific sub-groups, showed a 
trend towards improvement with statin use for all other endpoints: pneumonia 33% 
reduction (AOR of 0.67; 95% CI 0.43 – 1.04, p = 0.08), bacteremia 29% reduction in risk 
(AOR of 0.71; 95% CI 0.32 – 1.39, p = 0.40), urinary tract infection 35% reduction 
(AOR of 0.65; 95% CI 0.31 – 1.39, p = 0.27), and leg vein harvest site infection risk was 
reduced by 1% (AOR 0.99; 95% CI 0.30 – 3.26, p = 0.99). Oddly, the study found that 
deep sternal wound infection risk was increased by 20% (AOR of 1.20; 95% CI 0.44 – 
3.25, p = 0.72). There was also an association (but not statistically significant) of reduced 
risk of death with an AOR of 0.85 (95% CI 0.51 – 1.43, p = 0.54) and a statistically 
significant reduction in length of stay (AOR 0.80; 95% CI 0.64 – 0.99, p = 0.04). Several 
independent predictors of infection were identified, including: history of diabetes, COPD, 
morbid obesity, valve surgery, longer perfusion time during the operation, and red blood 
cell use during the operation.  
 
In the current study, we expand on the previously outlined hypotheses on the pleiotropic 
effects of statins on inflammation, sepsis, and 30 day mortality in medicine and surgical 
patients and apply it to non-cardiac and vascular surgical patients. 
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Section 5: Statement of Purpose 
 
The purpose of this study is to determine the role preoperative statin therapy has on 
postoperative infectious complications and 30 day postoperative mortality in general and 
non-cardiac surgical patients.  
 
Specific Hypothesis 
We believe that general and vascular surgery patients receiving statins prior to admission 
will have a reduced risk of postoperative infections and reduce 30 day postoperative 
mortality.  
 
Specific Aims Of The Thesis 
The primary outcome measure will be the development of any postoperative infectious 
complication. Postoperative infectious complications will include sepsis, septic shock, 
pneumonia, urinary tract infection, surgical site infection, deep surgical site infection, and 
wound disruption. Secondary outcomes include incidence of each of the postoperative 
infectious complications and 30 day mortality. We will also perform a multivariable 
logistic regression to account for factors that may confound the effect of statins. We hope 
to demonstrate that statins reduce postoperative infectious complication in general 
surgery and vascular surgery patients and reduce the risk of 30-day morality. 
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Section 6: Methods 
Study Design 
The approach and methods of the American College of Surgeons National Surgical 
Quality Improvement Program have been previously described in detail 88-92.  Between 
1991 and 1993, the National Veterans Affairs Surgical Risk Study (NVASRS) was 
conducted at 44 VA Medical Centers (VAMCs) to develop and validate risk-adjustment 
models for predicting surgical outcomes 93.  This study was undertaken in response to a 
Congressional law passed in 1986 that required VAMCs to report operative mortality 
rates and compare them to the national average.  Since there was not a consensus on 
national operative mortality rates for various surgical disciplines, the NVASRS was 
created.  Ultimately, this effort was accomplished to improve the delivery of surgical care 
at all VAMCs and to comply with the congressional mandate.  
Trained surgical nurses collected and entered data for each participating VAMC in order 
to be certain information on preoperative, perioperative, and 30-day outcomes was 
standardized.  Each outcome variable was clearly defined.  These data were then 
submitted to a central data analysis center and risk-adjusted models of general surgical 
outcomes were created and validated.  These risk-adjusted models were then expanded to 
include vascular surgery, orthopaedics, urology, thoracic (non-cardiac), and several other 
disciplines 90.  The goal was to be able to appropriately monitor and evaluate the quality 
of the surgical care at all VAMCs and have the ability to make necessary changes to 
improve performance.  
The VA National Surgical Quality Improvement Program (VA NSQIP), which started in 
1994, is an extension of the initial NVASRS.  It allowed participating VAMCs to be able 
to continue to report on operative mortality rates while making improvements based on 
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the information they collected.  In 2004, the model was adopted by the American College 
of Surgeons (ACS) and disseminated to a variety of non-VA hospitals.  
In both the VA and the ACS NSQIP programs, data collected by the NSQIP nurses 
include total number of procedures by surgical specialty, inpatient or outpatient status, 
and  major or minor status (based on specific type of procedure and type of anesthesia 
used) 90.  In addition risk-adjustment data is collected which includes 45 pre-surgical, 17 
surgical, and 33 outcomes variables 90.  These data are entered into each institution’s 
local database and are submitted to national data processing center to create the risk 
adjusted models.  Thirty days mortality and morbidity are reported as observed to 
expected ratios.  The ACS NSQIP has been verified as a consistent and accurate source of 
data on surgical outcomes.  
 The present study is a retrospective review of the ACS NSQIP data from the Brigham 
and Women’s Hospital (BWH), a 777-bed hospital affiliated with Harvard Medical 
School (HMS) from January 1, 2006 to January 1, 2008. We received approval from the 
Human Subjects Office at our institution prior to the start of the study.  Pharmacy data 
from the BWH pharmacy database were extracted for the same time period and the 
patient medical record number (MRN) was matched with the ACS NSQIP MRN for the 
same time period.  If the patient was receiving a statin preoperatively, it was noted and 
recorded, and confirmed with inpatient statin records.  
 
Study Population 
The study population included all non-cardiac, general and vascular surgery patients 
above the age of 18 admitted to the inpatient surgical floor.  Patients included men and 
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women of any race who were admitted for emergent and non-emergent procedures. 
Excluded were patients under age 18, those undergoing cardiac surgery, and those 
undergoing outpatient surgical procedures.  
 
Data Collection 
As per the ACS NSQIP protocol, trained surgical clinical nurses prospectively input a 
series of objective variables for operative morbidity and morality risk into the BWH local 
NSQIP.  Included in the data entry were presurgical characteristics (age, race, presurgical 
WBC, American Society of Anesthesiology classification or ASA, diabetic status on 
insulin or oral therapy, steroid therapy, type of case, and urgency of case), perioperative 
characteristics (use of intraoperative RBC, length of operation), and postoperative 
characteristics (length of hospital stay, occurrence of postoperative infectious 
complications, and 30 day postoperative mortality).  Postoperative infectious 
complications (POIC) included sepsis, septic shock, pneumonia (PNA), urinary tract 
infection (UTI), surgical site infection (SSI), deep surgical site infection (DSSI), or 
wound disruption (WD). The ACS NSQIP, for standardized collection purposes, defined 
POIC for all institutions that participate, based on guidelines from the Center for Disease 
Control and Prevention (CDC) 93.  ASA, a powerful predictor of surgical risk, was 
determined by placing the patient into one of five categories based on the patient’s health 
status (ASA 6, a moribund patient under-going organ procurement, was not applicable in 
this study).  In analysis, ASA 4 and ASA 5 classifications were combined into one 
classification (noted as ASA 4-5).  ASA 1 is reserved for a patient who is healthy, ASA 2 
for a patient with mild systemic disease, ASA 3 for a severe systemic disease, ASA 4 for 
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a patient with a life-threatening systemic disease, and ASA 5 for a patient not expected to 
survive greater than 24 hours without surgery 97,98.  Pharmacy data from the hospital’s 
electronic computerized physician order entry and pharmacy database was extracted by a 
pharmacist at BWH and placed in an excel file.  This list contained information on 
whether or not the patient was receiving and statin, and if so, the type of statin and 
dosage.  This file, which included the patient’s MRN and date of admission, was then 
merged with the BWH ACS NSQIP database for the similar time period and matched by 
MRN.  
 
Outcome Measures 
The primary outcome measure was the combined occurrence of any postoperative 
infectious complication (POIC). Secondary outcome measures included 30 day 
postoperative mortality, individual POIC, and length of hospital stay. 
 
Statistical Analysis 
The BWH ACS NSQIP and pharmacy records were merged and sorted on an excel sheet 
by MRN.  SAS statistical software, version 9.1 (SAS Institute Inc, Cary, North Carolina) 
was used to perform all analyses of the data.  A Wilcoxon rank sum test was performed 
for comparing continuous variables in the dataset.  Fisher exact test was performed to 
determine differences in proportions between two groups for dichotomous and 
categorical variables.  Multivariate logistic regression was used to determine if statins 
were an important predictor for dichotomous outcome. 
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Section 7: Results 
Demographic and Clinical Data of Patients Receiving Statins 
A total of 2,584 patients met the criteria of the study and were included in analysis.  Of 
these, 578 were on statin therapy at the time of admission and subsequently received 
statin therapy on the surgical floor.  The characteristics of the patients are featured in 
Table 1.  Patients receiving statins tended to be older (66.5 ± 11.5 years versus 51.75 ± 
15.6 years, p<0.0001), were less likely to undergo a general surgery procedure (58% of 
patients with statins underwent general surgery procedures versus 95% of the non-statin 
group, p <0.001), have greater surgical risk determined through ASA, were more likely to 
be diabetic (27% of statin patients versus 9% of the non-statin patients), were more likely 
to be receiving steroids (5.5% of statin patients received steroids versus 2.7% of the non-
statin group, p = 0.039). Intraoperatively, patients on statins tended to receive more units 
of RBC (8% of statin patients received >2 units of RBC versus 2% of the non-statin 
group, p = 0.00025) and have longer operations (statin group had a mean length of 
operation of 2.68 ± 1.8 hours versus a mean length of operation of 2.38 ± 1.4 hours for 
the non-statin group, p = 0.006).  Postoperatively, statin patients tended to have a longer 
hospital length of stay (statin patients had a mean stay of 7.8 days versus 5.5 days for the 
non-statin group).  There was no significant association between race, urgency of the 
case, or preoperative WBC. 
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TABLE 1: Demographic and Clinical Characteristics of Patients Receiving Statins 
 Demographic and Clinical Data by Statin 
 Statin Group Non-statin Group p value 
    
Age ± mean SD (yr) 66.5 ± 11.5 51.75 ± 15.6 <0.0001 
n 578 2006  
    
Race    
Black 48 (9%) 168 (9.3%)  
Other 5 (1%) 30 (1.6%)  
White 479 (90%) 1598 (88.9%)  
    
General Surgery 
Procedure    
yes 136 726 <0.0001 
no 98 36  
    
Emergent    
yes 61 186 0.319 
no 507 1805  
    
ASA    
1 2 74 <0.0001 
2 86 476  
3 136 205  
4-5 10 7  
    
Diabetes    
insulin 33 26 <0.0001 
oral 31 42  
no 170 694  
    
Steroids    
yes 13 741 0.039 
no 221 21  
    
Preoperative WBC 
(103/mm3) 8.99 8.42  
n 310 1039  
    
Units of RBC    
0-2 units 215 741 0.00025 
>2 units 19 21  
    
Length of Operation (hr) 2.68 ± 1.8 2.38 ± 1.4 0.006 
n 569 1991  
    
Length of Stay (days) 7.81 5.52 <0.0001 
n 576 1994  
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Demographic and Clinical Data, Infectious Complication 
There were a total of 224 POIC, 74 of which occurred with patients on statins. The 
characteristics of the patients are featured in Table 2. Infectious complications occurred 
in patients that tended to be older (59.6 ± 15.6 years versus 54.6 ± 16.0 years, p<0.0001), 
have greater surgical risk determined through ASA, and were more likely to be diabetic 
(21% of patients with an infectious complication versus 12%).  Intraoperatively, patients 
with a POIC tended to receive more units of RBC (10% of patients with a POIC received 
>2 units of RBC versus 3%, p = 0.001) and have longer operations (the POIC group had a 
mean length of operation of 3.14 ± 2.0 hours versus a mean length of operation of 2.38 ± 
1.4 hours, p < 0.0001).  Postoperatively, POIC patients tended to have a longer hospital 
length of stay (patients with a POIC had a mean stay of 12.1 days versus 8.6 days).  
There were no significant associations between pre-operative WBC, type of case, or 
steroid use.  
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TABLE 2: Demographic and Clinical Characteristics of Patients with at least one 
Postoperative Infectious Complication (POIC) 
 Demographic and Clinical Data by POIC 
 With infection No Infection p value 
    
Age ± mean SD (yr) 59.67 ± 15.66 54.62 ± 16.05 <0.0001 
n 224 2360  
    
Race    
Black 20 (9.95%) 196 (9.21%)  
Other 1  (0.49%) 34 (1.59%)  
White 180 (89.5%) 1897 (89.18%)  
    
General Surgery 
Procedure    
yes 82 (82.8%) 780 (86.9%) <0.0001 
no 17 (17.1%) 117 (13%)  
    
Emergent    
yes 40 (18%) 207 (8.85%) 0.319 
no 181 (81.9%) 2131 (91.15%)  
    
ASA    
1 3 73 <0.0001 
2 32 530  
3 62 279  
4-5 2 15  
    
Diabetes    
insulin 13 46 0.005 
oral 8 65  
no 78 786  
    
Steroids    
yes 6 28 0.126 
no 93 869  
    
Pre-Operative WBC 
(103/mm3) 9.26 8.48 0.023 
n 125 1224  
    
Units of RBC    
0-2 units 89 867 0.0011 
>2 units 10 30  
    
Length of Operation (hr) 3.14 ±2.037 2.38 ±1.45 <0.001 
n 221 2339  
    
Length of Stay (days) 13.73 5.3 <0.0001 
n 223 2347  
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Primary and Secondary Outcomes  
ASA, length of operation, and urgency of case were identified as independent risk factors 
for POI and were included in multivariate analysis, shown in Table 3.  
 
TABLE 3. Independent Predictors POIC 
 
Independent variable AOR 95% CI p-value 
Pre-operative statin use 0.978 0.584 1.637 0.932 
ASA classification 2.526 1.698 3.758 <0.0001 
Length of Operation 2.054 1.198 3.52 0.0088 
Emergency of case 2.855 1.568 5.201 0.0006 
 
Patients receiving statins, when adjusted for ASA classification, length of operation, and 
case emergency, had a slightly reduced risk of POI that was not significant  [AOR 0.978 
(95% CI 0.58 – 1.63, p = 0.93)].  Statin patients had a non-statistically significant 
reduction in risk for unadjusted DSSI and WD.  Patients receiving statins had an 
increased risk of sepsis and septic shock, although these were not statistically significant. 
Patients with statins that were diagnosed with PNA had an unadjusted reduced risk of 
68% (OR 0.321 CI 0.17 – 0.58, p = 0.0003).  However, in the adjusted analysis, patients 
receiving statins actually had an increased risk of pneumonia, with an AOR of 1.75, 
although this difference was not statistically significant (95% CI 0.93 – 3.30, p = 0.08). 
Statin patients had a reduced risk of UTI, with an unadjusted OR of 0.40 (95% CI 0.20 – 
0.80, p = 0.01).  SSI for patients receiving statins had an unadjusted OR of 0.65 (95% CI 
0.43 – 1.00, p = 0.06), but was not statistically significant when adjusted.  Patients 
receiving statins did have a significant reduction in risk of 30 day postoperative mortality 
with an OR of 0.45 (95% CI 0.23 – 0.87, p = 0.019).  These results are summarized in 
Table 4 and Table 5. 
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TABLE 4. Unadjusted Impact of Preoperative Statin use on Secondary Endpoints 
 
Endpoint  Unadjusted Analysis  
 OR 95% CI p-value 
Sepsis 1.02 0.48 2.15 0.999 
Septic Shock 2.88 0.37 22.61 0.47 
PNA 0.321 0.17 0.58 0.0003 
UTI 0.4 0.2 0.8 0.01 
SSI 0.65 0.43 1 0.06 
DSSI 0.35 0.095 1.33 0.119 
WD 0.67 0.17 2.6 0.47 
30-day Mortality 0.45 0.23 0.87 0.019 
     
  
 
TABLE 5. Adjusted Impact of Preoperative Statin use on Primary and Secondary 
Endpoints 
 
Endpoint  Adjusted Analysis  
 AOR 95% CI p-value 
Composite Endpoint 0.978 0.58 1.63 0.93 
PNA 1.75 0.93 3.3 0.08 
SSI 1.01 0.46 2.21 0.97 
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Section 8: Discussion 
Our results showed that general surgery patients receiving statins had an adjusted 
reduction in risk of POIC of 3%, which did not reach statistical significance, and a 55% 
reduction in risk in 30 day mortality.  The reduction in 30 day postoperative mortality 
mirrored the trend published by other authors 23, 24, 73, 80, 84, 86, 94.   In addition, we 
were able to identify independent risk factors of POIC, which included ASA, length of 
operation and urgency of care.  We also confirmed that length of stay for patients with  a 
postoperative infectious complication was over 2.5 times the length of stay for patients 
without such a complication.  
 
Similar to the only other study to explore postoperative infectious complications in the 
surgical patient (the Coleman study explored the role of statins in cardiac surgery), we 
were not able to achieve statistical significance in our sub-group analysis of individual 
POIC 82.  This was due to inadequate power and would require many more patients to be 
enrolled in order to appropriately analyze each type of POIC.  However, we were able to 
demonstrate similar results on postoperative mortality.  
 
Our study sought to prove that preoperative statin use would result in a reduction of 
POIC.  In fact, we were unable to demonstrate this effect as profoundly as we had hoped, 
despite evidence of statins ability to reduce the severity pneumonia and sepsis 21, 24, 28, 
69, 73, 74.  It is possible that since our statin group was older, had higher ASA scores, 
more diabetics, receiving steroids, and more general surgery procedures, the cohort was 
not comparable to the non-statin group.  Studies have shown that DM and nutritional 
status (more importantly, malnutrition) are risk factors for SSI 96.  It is possible that we 
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did not account for such determinants of postoperative infectious outcomes like 
malnutrition, socioeconomic status, or other unknown risk factors for infection.  While 
we identified ASA, emergency of case, and length of operation as independent risk 
factors, it is entirely possible that we failed to identify other factors not collected in the 
ACS NSQIP or that our sample size was not sufficient to identify other contributing 
factors. 
 
Other studies have shown a benefit to calculating an APACHE II score for admitted 
patients to characterize health status. No APACHE II score was done on admission, 
which could have served as another indicator of health status, the way that ASA 
classification serves as a marker for risk in surgery. Similarly, a pneumonia severity 
index could have been helpful in assessing the severity of the cases of pneumonia. 
Of note, a study by Fernandez et al found that statins increased mortality in ICU patients 
and felt that this was not due to the effects of statins, but in fact that statins were possibly 
a marker of severity in their ICU patients (sicker patients were on statins) 71. 
Interestingly, the Fernandez study included both medical and surgical patients admitted to 
their ICU. Lastly, CRP levels were not taken and could have been a useful marker of 
inflammation, but in a retrospective study, there would not have been any way to collect 
that information using the hospital database information and the ACS NSQIP. 
 
Limitations 
Retrospective observational cohort studies, by default, are subject to bias as these types 
of studies are not as tightly controlled as double-blinded, randomized control trials. We 
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tried to account for as much bias and confounders through multivariate logistic 
regression. However, the sample size was too small to allow adjustment for all of the 
factors know to be associated with postoperative infections. In addition, factors out of our 
control (specificity of data into the pharmacy database,  variables entered into the ACS 
NSQIP) still remain. Other potential uncontrolled confounding variables were the timing 
in the administration of other treatments (antibiotics, other vital medications), which may 
have differed between groups. Similarly, different surgeons and their surgical outcomes 
could potentially impact the results of this study, particularly since we do not have a very 
large sample size of patients in each specific postoperative infections outcome. By 
making the study multi-centered, we could increase the number of postoperative 
infectious events. Likewise, a randomized-control trial could be beneficial, but the ethics 
of doing so may be controversial as the association of preoperative statin use and at least 
30-day mortality rate has been well documents. Yet, the dosage, type of statin, timing, 
and what post-operative infectious complication benefits from stain use remains to be 
properly enumerated. We were able to confirm that there was a benefit in 30-day 
mortality. However, the role of statins in postoperative infectious complications in the 
non-cardiac and general surgery patient remains unknown. 
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